Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
Institut Jules Bordet · Université Libre de Bruxelles · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
567
total citations
- FWCI
- 47.50
- Percentile
- 100%
- References
- 42
Citations per year
Authors
20- MPMartine PiccartCorresponding
Institut Jules Bordet, Université Libre de Bruxelles
- GNGabriel N. Hortobágyi
The University of Texas MD Anderson Cancer Center
- MCMario Campone
Institut de Cancérologie de l'Ouest
- KIKathleen I. Pritchard
University of Toronto, Sunnybrook Health Science Centre
- FLFabienne Lebrun
Institut Jules Bordet, Université Libre de Bruxelles
Topics & keywords
Topics
Keywords
- Medicine
- Exemestane
- Human Epidermal Growth Factor Receptor 2
- Everolimus
- Oncology
- Internal medicine
- Hormone receptor
- Breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.